What’s Next? Five Things To Look Out For In April
Teva’s Austedo Set To Face ANDA Filings
Executive Summary
In April, four Humira (adalimumab) biosimilars are to be listed on Australia’s Pharmaceutical Benefits Scheme, while first-quarter financial reports will hit the market.